Rhinosinusitis: Establishing definitions for clinical research and patient care

Eli O. Meltzer; Daniel L. Hamilos; James A. Hadley; Donald C. Lanza; Bradley F. Marple; Richard A. Nicklas; Claus Bachert; James Baraniuk; Fuad M. Baroody; Michael S. Benninger; Itzhak Brook; Badrul A. Chowdhury; Howard M. Druce; Stephen Durham; Berrylin Ferguson; Jack M. Gwaltney; Michael Kaliner; David W. Kennedy; Valerie Lund; Robert Naclerio; Ruby Pawankar; Jay F. Piccirillo; Patricia Rohane; Ronald Simon; Raymond G. Slavin; Alkis Togias; Ellen R. Wald; S. James Zinreich

doi:10.1016/j.jaci.2004.09.029

Rhinosinusitis: Establishing definitions for clinical research and patient care

Eli O. Meltzer, Daniel L. Hamilos, James A. Hadley, Donald C. Lanza, Bradley F. Marple, Richard A. Nicklas, Claus Bachert, James Baraniuk, Fuad M. Baroody, Michael S. Benninger, Itzhak Brook, Badrul A. Chowdhury, Howard M. Druce, Stephen Durham, Berrylin Ferguson, Jack M. Gwaltney, Michael Kaliner, David W. Kennedy, Valerie Lund, Robert NaclerioRuby Pawankar, Jay F. Piccirillo, Patricia Rohane, Ronald Simon, Raymond G. Slavin, Alkis Togias, Ellen R. Wald, S. James Zinreich

Research output: Contribution to journal › Article › peer-review

661 Scopus citations

Original language	English
Pages (from-to)	155-212
Number of pages	58
Journal	Journal of Allergy and Clinical Immunology
Volume	114
Issue number	6 SUPPL.
DOIs	https://doi.org/10.1016/j.jaci.2004.09.029
State	Published - Dec 2004

Keywords

Rhinosinusitis
clinical trials
nasal polyposis
quality of life
sinusitis

Access to Document

10.1016/j.jaci.2004.09.029

Cite this

Meltzer, E. O., Hamilos, D. L., Hadley, J. A., Lanza, D. C., Marple, B. F., Nicklas, R. A., Bachert, C., Baraniuk, J., Baroody, F. M., Benninger, M. S., Brook, I., Chowdhury, B. A., Druce, H. M., Durham, S., Ferguson, B., Gwaltney, J. M., Kaliner, M., Kennedy, D. W., Lund, V., ... Zinreich, S. J. (2004). Rhinosinusitis: Establishing definitions for clinical research and patient care. Journal of Allergy and Clinical Immunology, 114(6 SUPPL.), 155-212. https://doi.org/10.1016/j.jaci.2004.09.029

@article{3dbef771dc464c12baea89565116f12a,

title = "Rhinosinusitis: Establishing definitions for clinical research and patient care",

keywords = "Rhinosinusitis, clinical trials, nasal polyposis, quality of life, sinusitis",

author = "Meltzer, {Eli O.} and Hamilos, {Daniel L.} and Hadley, {James A.} and Lanza, {Donald C.} and Marple, {Bradley F.} and Nicklas, {Richard A.} and Claus Bachert and James Baraniuk and Baroody, {Fuad M.} and Benninger, {Michael S.} and Itzhak Brook and Chowdhury, {Badrul A.} and Druce, {Howard M.} and Stephen Durham and Berrylin Ferguson and Gwaltney, {Jack M.} and Michael Kaliner and Kennedy, {David W.} and Valerie Lund and Robert Naclerio and Ruby Pawankar and Piccirillo, {Jay F.} and Patricia Rohane and Ronald Simon and Slavin, {Raymond G.} and Alkis Togias and Wald, {Ellen R.} and Zinreich, {S. James}",

note = "Funding Information: Disclosure of potential conflict of interest: E. O. Meltzer has consulting arrangements with Alcon, Altana, AstraZeneca, Aventis, Dey, Genentech, GlaxoSmithKline, Merck, Medpointe, Novartis, Pfizer, Schering-Plough, and Wyeth; receives grants–research Support from Alcon, Altana, AstraZeneca, Aventis, Dey, Genetech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Schering-Plough; and is on the Speakers' Bureau for Aventis, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Pfizer, and Schering-Plough. D. L. Hamilos—none disclosed. J. A. Hadley has consultant arrangements with Abbott, Aventis, Bayer, GlaxoSmithKline, Merck, GE Medical Systems, Pfizer, and Schering-Plough; and is on the Speaker's Bureau for Abbott, Aventis, Bayer, GlaxoSmithKline, Merck, Pfizer, and Schering-Plough. D. Lanza is on the Speaker's Bureau for AstraZeneca. B. F. Marple has consulting arrangements with Alcon, Aventis, and Bayer and receives grants-research support from Aventis, GlaxoSmithKline, Abbott, Merck, and Bayer. R. A. Nicklas—none disclosed. C. Bachert—none disclosed. J. Baraniuk has consultant arrangements with Roche, Centecor, GlaxoSmithKline, Astra-Zeneca, and Aventis; has patent-licensing arrangements with Georgetown University; receives grants-research support from the National Institutes of Health; and is employed by Georgetown University. F. M. Baroody is on the Speaker's Bureau for Merck & Co, Inc, and GlaxoSmithKline. M. S. Benninger has consultant arrangements with Aventis, GlaxoSmithkline, Ortho-McNeil, Abbott, and Bayer; receives grants–research support from Novartis and Bayer; is on the Speaker's Bureau for Aventis and GlaxoSmithKline. I. Brook is on the Speaker's Bureau for Abbott. B. A. Chowdhury—none disclosed. H. M. Druce is employed by Phys Inc. S. Durham has consultant arrangements with ALK Abello, UCB, and GlaxoSmithKline; receives grants–research support from ALK Abello and GalxoSmithKline; and is on the Speaker's Bureau for ALK Abello, UCB, Aventis, and WAO. B. Ferguson has consulting arrangements with Aventis, Abbot, and GlaxoSmithKline; is on the Speaker's Bureau for Aventis, Astra Zeneca, Abbott, Merck, GlaxoSmithKline, and Pfizer; and is an advisor for Pfizer. J. M. Gwaltney, Jr—none disclosed. M. Kaliner has consultant arrangements with Aventis, Novartis, GlaxoSmithKline, Genetech, and Abbott; receives grants–research support from Astra Zeneca, Aventis, Boehringher-Ingelheim, GlaxoSmithKline, and Schering-Plough; and is on the Speaker's Bureau for Aventis, Abbott, GlaxoSmithKline, Medpointe, Novartis, and Genetech. D. Kennedy has consulting arrangements with Aventis, Novartis, Medtronic-Xomed, and Schering-Plough; received grants–research support from Novartis; and has patent-licensing arrangements with Medtronic-Xomed. V. Lund has consulting arrangements with Schering-Plough and Bayer. R. Naclerio has consulting arrangements with Merck and Schering-Plough; receives grants–research support from Corixa and Merch; and is on the Speaker's Bureau for Merck and GlaxoSmithKline. R. Pawankar—none disclosed. J. F. Piccirillo—none disclosed. P. Rohane is employed by Celgene Corp. R. Simon—none disclosed. R. Slavin has consultant arrangements with Aventis; receives grants–research support from GlaxoSmithKline, Genentech, and AstraZeneca; and is on the Speaker's Bureau of Aventis, Schering-Plough, Genentech, and AstraZeneca. A. Togias has consultant arrangement with AstraZeneca, Genentech, GlaxoSmithKline, Novartis, and Merck; receives grants–research support from Merck and Genentech; and is on the Speaker's Bureau for Genentech, Merck, Novartis, Pfizer, and UCB. E. R. Wald receives grants—research support from Aventis, GlaxoSmithKline, Wyeth, Abbott, and Medimmune. J. Zinreich—none disclosed. ",

year = "2004",

month = dec,

doi = "10.1016/j.jaci.2004.09.029",

language = "English",

volume = "114",

pages = "155--212",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

number = "6 SUPPL.",

}

Meltzer, EO, Hamilos, DL, Hadley, JA, Lanza, DC, Marple, BF, Nicklas, RA, Bachert, C, Baraniuk, J, Baroody, FM, Benninger, MS, Brook, I, Chowdhury, BA, Druce, HM, Durham, S, Ferguson, B, Gwaltney, JM, Kaliner, M, Kennedy, DW, Lund, V, Naclerio, R, Pawankar, R, Piccirillo, JF, Rohane, P, Simon, R, Slavin, RG, Togias, A, Wald, ER & Zinreich, SJ 2004, 'Rhinosinusitis: Establishing definitions for clinical research and patient care', Journal of Allergy and Clinical Immunology, vol. 114, no. 6 SUPPL., pp. 155-212. https://doi.org/10.1016/j.jaci.2004.09.029

TY - JOUR

T1 - Rhinosinusitis

T2 - Establishing definitions for clinical research and patient care

AU - Meltzer, Eli O.

AU - Hamilos, Daniel L.

AU - Hadley, James A.

AU - Lanza, Donald C.

AU - Marple, Bradley F.

AU - Nicklas, Richard A.

AU - Bachert, Claus

AU - Baraniuk, James

AU - Baroody, Fuad M.

AU - Benninger, Michael S.

AU - Brook, Itzhak

AU - Chowdhury, Badrul A.

AU - Druce, Howard M.

AU - Durham, Stephen

AU - Ferguson, Berrylin

AU - Gwaltney, Jack M.

AU - Kaliner, Michael

AU - Kennedy, David W.

AU - Lund, Valerie

AU - Naclerio, Robert

AU - Pawankar, Ruby

AU - Piccirillo, Jay F.

AU - Rohane, Patricia

AU - Simon, Ronald

AU - Slavin, Raymond G.

AU - Togias, Alkis

AU - Wald, Ellen R.

AU - Zinreich, S. James

N1 - Funding Information: Disclosure of potential conflict of interest: E. O. Meltzer has consulting arrangements with Alcon, Altana, AstraZeneca, Aventis, Dey, Genentech, GlaxoSmithKline, Merck, Medpointe, Novartis, Pfizer, Schering-Plough, and Wyeth; receives grants–research Support from Alcon, Altana, AstraZeneca, Aventis, Dey, Genetech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Schering-Plough; and is on the Speakers' Bureau for Aventis, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Pfizer, and Schering-Plough. D. L. Hamilos—none disclosed. J. A. Hadley has consultant arrangements with Abbott, Aventis, Bayer, GlaxoSmithKline, Merck, GE Medical Systems, Pfizer, and Schering-Plough; and is on the Speaker's Bureau for Abbott, Aventis, Bayer, GlaxoSmithKline, Merck, Pfizer, and Schering-Plough. D. Lanza is on the Speaker's Bureau for AstraZeneca. B. F. Marple has consulting arrangements with Alcon, Aventis, and Bayer and receives grants-research support from Aventis, GlaxoSmithKline, Abbott, Merck, and Bayer. R. A. Nicklas—none disclosed. C. Bachert—none disclosed. J. Baraniuk has consultant arrangements with Roche, Centecor, GlaxoSmithKline, Astra-Zeneca, and Aventis; has patent-licensing arrangements with Georgetown University; receives grants-research support from the National Institutes of Health; and is employed by Georgetown University. F. M. Baroody is on the Speaker's Bureau for Merck & Co, Inc, and GlaxoSmithKline. M. S. Benninger has consultant arrangements with Aventis, GlaxoSmithkline, Ortho-McNeil, Abbott, and Bayer; receives grants–research support from Novartis and Bayer; is on the Speaker's Bureau for Aventis and GlaxoSmithKline. I. Brook is on the Speaker's Bureau for Abbott. B. A. Chowdhury—none disclosed. H. M. Druce is employed by Phys Inc. S. Durham has consultant arrangements with ALK Abello, UCB, and GlaxoSmithKline; receives grants–research support from ALK Abello and GalxoSmithKline; and is on the Speaker's Bureau for ALK Abello, UCB, Aventis, and WAO. B. Ferguson has consulting arrangements with Aventis, Abbot, and GlaxoSmithKline; is on the Speaker's Bureau for Aventis, Astra Zeneca, Abbott, Merck, GlaxoSmithKline, and Pfizer; and is an advisor for Pfizer. J. M. Gwaltney, Jr—none disclosed. M. Kaliner has consultant arrangements with Aventis, Novartis, GlaxoSmithKline, Genetech, and Abbott; receives grants–research support from Astra Zeneca, Aventis, Boehringher-Ingelheim, GlaxoSmithKline, and Schering-Plough; and is on the Speaker's Bureau for Aventis, Abbott, GlaxoSmithKline, Medpointe, Novartis, and Genetech. D. Kennedy has consulting arrangements with Aventis, Novartis, Medtronic-Xomed, and Schering-Plough; received grants–research support from Novartis; and has patent-licensing arrangements with Medtronic-Xomed. V. Lund has consulting arrangements with Schering-Plough and Bayer. R. Naclerio has consulting arrangements with Merck and Schering-Plough; receives grants–research support from Corixa and Merch; and is on the Speaker's Bureau for Merck and GlaxoSmithKline. R. Pawankar—none disclosed. J. F. Piccirillo—none disclosed. P. Rohane is employed by Celgene Corp. R. Simon—none disclosed. R. Slavin has consultant arrangements with Aventis; receives grants–research support from GlaxoSmithKline, Genentech, and AstraZeneca; and is on the Speaker's Bureau of Aventis, Schering-Plough, Genentech, and AstraZeneca. A. Togias has consultant arrangement with AstraZeneca, Genentech, GlaxoSmithKline, Novartis, and Merck; receives grants–research support from Merck and Genentech; and is on the Speaker's Bureau for Genentech, Merck, Novartis, Pfizer, and UCB. E. R. Wald receives grants—research support from Aventis, GlaxoSmithKline, Wyeth, Abbott, and Medimmune. J. Zinreich—none disclosed.

PY - 2004/12

Y1 - 2004/12

KW - Rhinosinusitis

KW - clinical trials

KW - nasal polyposis

KW - quality of life

KW - sinusitis

UR - http://www.scopus.com/inward/record.url?scp=9644300929&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2004.09.029

DO - 10.1016/j.jaci.2004.09.029

M3 - Article

C2 - 15577865

AN - SCOPUS:9644300929

SN - 0091-6749

VL - 114

SP - 155

EP - 212

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 6 SUPPL.

ER -

Rhinosinusitis: Establishing definitions for clinical research and patient care

Keywords

Access to Document

Other files and links

Cite this